Slovakia Pharmaceuticals & Healthcare Q4 2006

Published by: Business Monitor International

Published: Oct. 1, 2006 - 60 Pages

Table of Contents

Chapter 1 - Executive Summary

Industry SWOT Analysis

Slovakia Pharmaceuticals Industry SWOT

Slovakia Political SWOT

Slovakia Economics SWOT

Slovakia Business Environment SWOT

Chapter 2 - Business Environment Rankings

Central & Eastern European Region

Table: Central & Eastern Europe Pharmaceuticals - Business Environment Ranking

Business Environment Ranking

Economics - Long-Term Risk

Politics - Long-Term Risk

Regulatory Barriers

Domestic Sector Threat

Market Growth Potential

Market Size Ranking

Chapter 3 - Slovakia: Market Summary

Chapter 4 - Regulatory Regime

Intellectual Property Developments

Pricing and Reimbursement Issues

Chapter 5 - Industry Trends & Developments

Healthcare Sector

Healthcare Sector Strike

Table: Strike timeline (2006)

Healthcare Funding Crisis

Generics Sector

Chapter 6 - Industry Forecast Scenario

Overall Market Forecast

Table: Drug Market Indicators

Table: Health Expenditure Indicators

Key Growth Factors - Macroeconomic

Table: Growth & Output

Prescription Market Forecast

Table: Prescription Drug Market Indicators

OTC Market Forecast

Table: OTC Market Indicators

Generics Market Forecast

Table: Generics and Branded Market Indicators

Export/Import Forecasts

Table: Sectoral Trade Indicators

Other Healthcare Data Forecasts

Table: Socio-Demographic Indicators

Key Risks to BMI’s Forecast Scenario

Chapter 7 - Country Snapshot: Slovakia Demographic Data

Section 1: Population:

Table: Demographic Indicators (2005)

Table: Rural/Urban Breakdown

Section 2: Education & Healthcare

Table: Education

Table: Healthcare: Vital Statistics

Table: Healthcare: Expenditure

Section 3: Labour Market And Spending Power

Table: Employment Indicators

Table: Consumption and Stratification

Table: Wages per year

Chapter 8 - Competitive Landscape

Company Monitor

GlaxoSmithKline (GSK)

Imuna Pharma

Chapter 9 - BMI Forecast Modelling

How we generate our industry forecasts

Technical Process

Pharmaceutical Industry

Sources

Chapter 10 - Appendix: Regional Demographic Data

Wages (Ave. Labour Force Per Annum), US$ PPP

Population

Household Spending Per Capita, US$

Private Consumption Per Capita, US$ PPP

Market Size, GDP, US$bn

Abstract

The Slovakian pharmaceuticals market is poised for period of transition following the country's recent general election which saw the centre-left Smer party gain control from the centre-right SDKU party. Growth is now expected to be less than previously thought because of Smer's socialist leanings, according to BMI's newly-published ""Slovakia Pharmaceuticals & Healthcare Report"".

Nevertheless, the country is one of the more developed drug markets in the Central & Eastern European (CEE) region, with per capita drug expenditure estimated at US$126 in 2005. BMI's adjusted Business Environment Rankings for the CEE region reveal that Slovakia ranks seventh out of fourteen countries, just behind nations such as the Czech Republic and Poland. Slovakia scored highly on political risk and market growth potential, but was let down by market size.

Under the SDKU regimen, the country had almost eliminated crippling healthcare debts accrued since the dissolution of Czechoslovakia. However, success in cutting deficits clearly came at a cost, typified by the healthcare worker strikes that hit Slovakia in April 2006. Public funding - including government and social health insurance spending - accounted for about 89% of total health expenditure in 2000, well above the OECD average of 72%. The government intends to pay an additional SKK6bn (US$203mn) each year to health insurance companies for the people insured by the state.

Foreign pharmaceuticals firms are upbeat about investing in Slovakia after the country was removed from International Intellectual Property Alliance's 2006 list of countries deemed to be failing to provide sufficient intellectual property protection and fair market access. But a recent amendment to the Slovak medicines law that hinders the approval of generic medicines was criticised by both the country's generic medicines association and the European Generic Medicines Association. The amendment contained a provision allowing the Slovakian State Institute for Drug Control to refuse registration applications for generic versions of drugs that are still covered by a patent, which is against EU legislation.

Health Minister Ivan Valentovic's first goals are to stop the transformation of hospitals into joint-stock companies and to abolish the symbolic doctors' fees introduced by the previous regime. However, fellow member of the victorious coalition - the nationalist SNS party - believes that the fees are effective and wants to conduct a technical discussion on the matter with its partners.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.